Keytruda 100 MG/4 ML vial 4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FCFP2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $43,626
Award facts
- Contract value 100% obligated
- $43,625.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $43,625.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Keytruda (pembrolizumab) 100 mg/4 mL vials. The delivery order, issued on January 6, 2026, with an ultimate completion date of January 28, 2026, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This award was issued without subcontractors and represents a routine pharmaceutical supply transaction to support Department of Defense medical operations.
This delivery order was issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to supply pharmaceutical products and medical consumables to military healthcare facilities worldwide. The underlying IDC, designated SPE2DR and awarded November 13, 2025, provides a $499,999,999 ceiling with a completion date of December 31, 2036, structured with a 30-month base period and three 30-month option periods. DMS Pharmaceutical Group's selection as a prime vendor contractor demonstrates its established capability to deliver specialized oncology treatments and diverse pharmaceutical products critical to federal military medical system requirements globally.
Quick answers
Who was awarded contract SPE2DR26FCFP2?
SPE2DR26FCFP2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26FCFP2 worth?
The government has obligated $43,626 on SPE2DR26FCFP2.
Is contract SPE2DR26FCFP2 an order under another contract?
Yes. SPE2DR26FCFP2 is a delivery order under SPE2DR25D9133, an indefinite delivery contract.
Was contract SPE2DR26FCFP2 competed?
The extent of competition for SPE2DR26FCFP2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award